Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-Buffered Injection Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Pain Perception: Lidocaine Rate/Temp/Buffer

NCT02823002
View directory record Official record
Conditions
Pain
Interventions
Slow, Room Temperature Injection, Rapid, Room Temperature Injection, Slow, Warm Temperature Injection, Rapid, Warm Temperature Injection, Buffered Injection, Non-Buffered Injection, Lidocaine, Buffer
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 22, 2026, 4:37 PM EDT
Not yet recruiting Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke

NCT07813130
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
AB126 Neural Exosomes Intravenous Injection, AB126 Placebo
Biological · Other
Lead sponsor
Aruna Bio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CJCV2 With and Without ALFQ

NCT05500417
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ALFQ, CJCV2
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 22, 2026, 4:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Control With Osmotic Dilator Placement

NCT02354092
View directory record Official record
Conditions
Abortion Late, Pain
Interventions
Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control
Procedure · Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine

NCT02747186
View directory record Official record
Conditions
Anesthesia
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 22, 2026, 4:37 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

NCT03110952
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV, TDENV-F17, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00719043
View directory record Official record
Conditions
Influenza
Interventions
A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 22, 2026, 4:37 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine

NCT02620683
View directory record Official record
Conditions
Blood Levels of Buffered vs Non-buffered Lidocaine, Anesthetics, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 4:37 PM EDT
Terminated Phase 4 Interventional Results available

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Recruiting Not applicable Interventional

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

NCT03694756
View directory record Official record
Conditions
Breast Cancer
Interventions
TMEM-MRI, FNA
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 22, 2026, 4:37 PM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

NCT01019681
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Cord blood stem cell injection
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 22, 2026, 4:37 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 22, 2026, 4:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT07408583
View directory record Official record
Conditions
Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure Disorders, Genetic Diseases, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders, Cancer Predisposition Syndrome
Interventions
IUHSCT for FA-affected fetuses
Biological
Lead sponsor
Agnieszka Czechowicz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2033
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Faricimab
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Buffered Lidocaine in the Pediatric Dental Patient

NCT04055116
View directory record Official record
Conditions
Pediatric Dentistry
Interventions
Buffered Lidocaine
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
4 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 22, 2026, 4:37 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

NCT03127943
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 22, 2026, 4:37 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Montgomery, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 4:37 PM EDT